OAB0603	Changes in body mass index over time in persons with and without HIV	Oral abstract session with live Q&A	B22
OAB0602	Weight gain and hyperglycemia during the dolutegravir transition in Africa	Oral abstract session with live Q&A	B21
OAB0507	TB contact investigations as an active HIV case finding strategy in Mozambique: Lessons for high TB and HIV syndemic countries	Oral abstract session with live Q&A	B10
OAB0506	Validation of a laboratory-based reference test for TB-LAM and FLOW-TB, a novel point-of-care TB diagnostic assay, in a high-HIV-prevalence clinical cohort from KwaZulu-Natal, South Africa	Oral abstract session with live Q&A	B10
OAB0505	Risk factors for hepatotoxicity in HIV-infected women receiving isoniazid preventive therapy in pregnancy and postpartum	Oral abstract session with live Q&A	B10
OAB0504	Assessment of the tuberculosis clinical cascade among children living with HIV on antiretroviral therapy, 16 Sub-Saharan PEPFAR-supported programs, October 1, 2018 to March 31, 2019	Oral abstract session with live Q&A	B10
OAB0503	Prevalence and incidence of tuberculosis infection and disease among household contacts exposed to rifampin-resistant/multidrug resistant tuberculosis (RR/MDR-TB)	Oral abstract session with live Q&A	B10
OAB0502	Efficacy and safety outcomes (HIV subgroup analysis) in the Nix-TB Trial - bedaquiline, pretomanid and linezolid for treatment of extensively resistant, intolerant or non-responsive pulmonary multidrug-resistant tuberculosis	Oral abstract session with live Q&A	B10
OAB0405	Sub-optimal outcomes with switching to zidovudine vs. recycling tenofovir in second-line treatment in Haiti	Oral abstract session with live Q&A	B30
OAB0404	Third-line antiretroviral therapy including raltegravir, darunavir/ritonavir and/or etravirine is well tolerated and achieves durable virologic suppression over 144+ weeks in resource limited settings ACTG: A5288 strategy trial	Oral abstract session with live Q&A	B31